EuroPCR 2021 | TVT Registry: Outcomes of TAVR in Low Surgical Risk Bicuspids

In bicuspid patients with aortic stenosis and low surgical risk, transcatheter aortic valve replacement (TAVR) with balloon expandable valve offers results comparable to normal anatomy results. 

Registro TVT: resultados del TAVI en bicúspides de bajo riesgo quirúrgico

These data come from the TVT registry, presented at EuroPCR 2021 scientific sessions.

Stroke and death rates (inhospital, 30 days and one year) in bicuspid patients did not result different to tricuspid patient rates. Both groups of patients also obtained similar benefits in valve area, gradients, functional class, and quality of life. 

These data show TAVR could be a reasonable option to treat patients with aortic stenosis, bicuspid anatomy and low surgical risk when carefully selected. 

Even though TAVR has long been approved by the FDA for the whole risk spectrum, studies providing evidence to support this claim have systematically excluded bicuspid anatomy. 

The authors of this study examined data of nearly 160,000 patients in the TVT registry undergoing TAVR with Sapien 3 or Sapien 3 ultra between 2015 and 2020. 


Read also: EuroPCR 2021 | A New Meta-Analysis Challenges the ISCHEMIA Trial.


Among them, 4.4% had bicuspid anatomy, and finally 3.168 presented low surgical risk (STS <3%). These fewer over 3,000 patients were compared using propensity score to tricuspid patients. 

Femoral access was used in 97% of both groups, but bicuspid patients less frequently received conscious sedation (57% vs 62%; p<0.001) and more often the largest device available (38% vs 30%; p<0.001).

Complications rate as conversion to conventional surgery, annulus rupture, need for bypass, aortic dissection, coronary obstruction or need for a second valve were low (<0.5%) in both groups.


Read also: EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development.


Paravalvular leak moderate to severe tended to be larger among the bicuspid, which calls for further study. 

There is no doubt followup should be longer and, ideally, we should carry out a specific randomized study on bicuspids before extending any recommendation for TAVR to low-risk patients and, in general, young patients who could clearly benefit from surgery. 

Original Title: Outcomes of transcatheter aortic valve replacement for bicuspid aortic valve stenosis in the low-surgical risk population.

Reference: Makkar R et al. Presentado en el EuroPCR 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Impact of Iliofemoral Disease on Post TAVR Clinical Outcomes: HOSTILE Score Validation

At present, transcatheter aortic valve replacement (TAVR) has been shown safe and effective for treating severe symptomatic aortic stenosis in high-surgical-risk patients. Moreover, its...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...